Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adults With Moderate-to-Severe Atopic Dermatitis

Next Previous
X
Search
Trial Profile

A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adults With Moderate-to-Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telazorlimab (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Proof of concept; Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals S.A.

    • Most Recent Events

    • 01 Mar 2019 According to a Glenmark Pharmaceuticals media release, a new post hoc analysis data from this study assessing the activity of GBR 830 in patients with intrinsic and extrinsic atopic dermatitis subtypes, and for subjects with elevated IgE levels at baseline, were presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.
    • 01 Mar 2019 Results of new post hoc analysis from this study presented in a Glenmark Pharmaceuticals media release.
    • 25 Feb 2019 Results of a post-hoc analysis assessing the activity of GBR 830 in patients with Intrinsic and Extrinsic Atopic Dermatitis, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top